NOV 27 2026
BridgeBio Pharma — BBP-418 $BBIO
for limb-girdle muscular dystrophy type 2I/R9
About
Limb-girdle muscular dystrophy type 2I/R9 is a genetic disorder that causes progressive weakness and wasting of the muscles in the shoulders and hips. BBP-418 is designed to increase the levels of a crucial sugar molecule that stabilizes muscle proteins. By boosting this natural stabilizer, the drug could potentially slow the muscle breakdown and loss of function in people with this condition.
Pivotal trial
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on BBP-418
- BridgeBio Priority Review Puts BBP-418 And Valuation In Investor Focus - simplywall.st
- FDA decision on BBP-418 for LGMD2i expected in late November - Muscular Dystrophy News
- BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Status - Quiver Quantitative
- BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - Yahoo Finance
- BridgeBio (BBIO) Secures FDA Filing Acceptance for BBP-418 - GuruFocus